Agoracom: Small Cap Investment - Mosaic ImmunoEngineering Inc. - Re: Two Considerations - 80% of Revenue going to TPL..a quick look at the last

Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Reply New Message

Prev Message Back To Forum Threaded View Next Message

FutTheWuk

Rank: President [?]

Points: 9784 [?]

Votes: 143 Score: 3.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Two Considerations - 80% of Revenue going to TPL..a quick look at the last

in response to

Re: Two Considerations - 80% of Revenue going to TPL

badgerboostr

posted on Mar 24, 2010 04:53PM

10Q shows that for that quarter PTSC showed licensing income of about 43% of the gross licensing amount for the quarter, which means overall the profit of PDS was about 86% of gross licensing. For the 6 months it equated to 63%. So obviously your 80/20 info in misinformation.

4 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply